Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...
Brian F. Sullivan, CEO, announced several milestones, including positive top line data from the PIK3CA wild-type cohort of the Phase III VIKTORIA-1 trial, initiation of dosing in the VIKTORIA-2 trial, ...
CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with ...
DENVER, Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of ...
VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis (FAP) is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated, ...
This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is ...
This expanded portfolio is expected to triple AVITA Medical’s addressable market in burns, as dermal matrices are a critical component of the standard two-stage surgical procedure for definitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback